Bevacizumab plus paclitaxel vs. bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: phase III TURANDOT trial interim results

Source: Lancet Oncology Area: News Randomised phase 3 trials in metastatic breast cancer have shown that combining bevacizumab with either paclitaxel or capecitabine improves progression-free survival (PFS) and response rate compared with chemotherapy alone but the relative efficacy of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine has not been investigated. These two regimens were thus compared in an open-label, non-inferiority, phase III trial [TURANDOT (capeciTabine and bevacizumab Randomised Against avastiN anD taxOl Trial)].   The trial was designed to answer three main questions:   1. Is overall survival with first-line bevacizumab plus capecitabine non-inferior to that with bevacizumab plus paclitaxel?   2. What is the efficacy of the two regimens in terms of other endpoints, including quality of life?   3. Do toxic effects limit the use of either paclitaxel or capecitabine in combination with bevacizumab?   The study ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news